EXEL
EXELIXIS, INC.
Nasdaq: EXEL · Alameda, CA · Healthcare
$45.89+2.28 (+5.23%)Closed
Market Cap$12.05B
Cash$1.06Bmost recent
Runwayprofitable
P/E (TTM)16.5EPS $2.78
52-Wk Range$34.54 – $46.61
Avg Volume2.9M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$45.89+100.7%
Pipeline
Drug candidates sponsored by EXELIXIS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Cabozantinib (XL184) 140 mg | Medullary Thyroid Cancer | Active, not recruiting | 2020-07-15past | 1 | |
| Phase 3 | XL184 | Thyroid Cancer+8 more | Completed | 2012-11past | 5 | |
| Phase 3 | Cabozantinib tablets | Renal Cell Carcinoma+1 more | Completed | 2017-10-16past | 2 | |
| Phase 3 | cabozantinib | Prostate Cancer+26 more | Active, not recruiting | 2024-04-19past | 13 | |
| Phase 3 | XL092 | Non-Clear Cell Renal Cell Carcinoma+5 more | Active, not recruiting | 2026-05 | 3 | |
| Phase 2 | Zanzalintinib | Head and Neck Squamous Cell Carcinoma+16 more | Recruiting | 2028-02 | 6 | |
| Phase 2 | XL820 | Gastrointestinal Stromal Tumors+2 more | Completed | 2009-05past | 3 | |
| Phase 1 | XL844 | Cancer+3 more | Terminated | 2008-12past | 2 | |
| Phase 1 | XL019 | Polycythemia Vera+3 more | Terminated | 2009-02past | 2 | |
| Phase 1 | XL647 | Cancer+2 more | Withdrawn | 2009-12past | 1 | |
| Phase 1 | XL888 | Cancer | Terminated | 2010-11past | 1 | |
| Phase 1 | XL228 | Cancer+3 more | Terminated | 2010-12past | 2 | |
| Phase 1 | XL281 | Cancer+4 more | Completed | 2011-10past | 1 | |
| Phase 1 | rosiglitazone | Papillary Thyroid Cancer+3 more | Completed | 2012-08past | 1 | |
| Phase 1 | cabozantinib capsules | Solid Tumors+2 more | Completed | 2015-05past | 1 | |
| Phase 1 | XL114 | Non-Hodgkin's Lymphoma (NHL)+4 more | Terminated | 2022-11-01past | 1 | |
| Phase 1 | XL102 | Neoplasm Malignant+4 more | Terminated | 2024-05-02past | 1 | |
| Phase 1 | XB002 | Non Small Cell Lung Cancer+10 more | Completed | 2025-03-10past | 1 | |
| Phase 1 | XL495 | Solid Cancers+6 more | Terminated | 2025-05-07past | 1 | |
| Phase 1 | XB010 | Locally Advanced or Metastatic Solid Tumors+5 more | Recruiting | 2026-11-23 | 1 | |
| Phase 1 | XB628 | Solid Tumor+3 more | Recruiting | 2027-05 | 1 | |
| Phase 1 | XB371 | Solid Tumors | Recruiting | 2027-11 | 1 | |
| Phase 1 | XL309 | Advanced Solid Tumor | Recruiting | 2029-01-03 | 1 | |
| Phase 1 | XL418 | Cancer+1 more | Suspended | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for EXEL. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.